Clinical trial NCT05396547: Study On The Performance And Safety Of The LEDINBIO CE Device On Visual Acuity In Subjects With Cataract
Official title: Study On The Performance And Safety Of The LEDINBIO CE Device On Visual Acuity In Subjects With Cataract
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Age-related Cataract
Keywords: non-invasive cataract treatment, N-LOCS III grade 1 to 3
Lead sponsor: Edinburgh Biosciences Ltd
Sponsor class: INDUSTRY
Collaborators: name: MDX Research
First posted: 2022-05-31
Enrollment: 114
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single arm interventional study
Primary purpose: TREATMENT

Brief summary: Single arm, unmasked study to evaluate the performance and safety of the LEDINBIO CE Device for the non-invasive treatment of vision loss in age-related cataract.

Detailed description: This single arm, unmasked study will evaluate the performance and safety of the LEDINBIO CE Device for the non-invasive treatment of vision loss in age-related cataract.

Only one of the subject's eyes will be treated with the LEDINBIO CE Device during the study (blue light treatment beam: Visit 1: 15 minutes, Visits 2 - 9: 20 minutes). The Treatment period will last 19 days (+ 1 day), starting with the day of first treatment (Visit 1, day 1). During this period, subjects will be treated with the LEDINBIO investigational device three-times a week for 3 weeks (Visit 1 to Visit 9) up to a maximum of 20 days (or 2.9 weeks). The Treatment period will be followed by 84 days (± 10 days) of follow up, up to a maximum of 94 days (or 13.4 weeks).

The subject's eyes will be examined throughout the study to allow safety and performance to be monitored. The safety examinations includes standard ophthalmological tests.

Clinical assessments in the study will use traditional ophthalmic methods including LogMAR best corrected visual acuity (BCVA) for distance, and grading of cataracts using LOCS III.

In addition, spectral data (fluorescent emission) will be collected using the LEDINBIO CE Device to monitor the progress of the treatment, and to determine the suitability of these measurements for future clinical diagnoses.

Eligibility criteria: Inclusion Criteria:

1. Subject diagnosed with nuclear sclerotic (NS) lens opacities cataract, LOCS III grade 1 to 3 (moderate), as confirmed by the Investigator
2. Subject aged between 40 and 85 years of age (inclusive) at the time of consent
3. Best Corrected Visual Acuity (BCVA) of 0.3 LogMAR or worse due to cataract only
4. Subject whom the medical health history has been reviewed by the Investigator and medical records do not contraindicate the participation to the study
5. Subject who is judged suitable for the study after ophthalmic examination carried out by the Investigator
6. Be able and willing to follow instructions, including participation in all study assessments and visits, according to the opinion of the investigator - including being able to sit upright for at least 20 mins (duration of the treatment)

Exclusion Criteria:

1. Subject unable to give voluntary written informed consent, is unlikely to cooperate or is legally incompetent, including subjects who are institutionalised by court or official order, or in a dependency relationship with sponsor, testing centre or investigator
2. Subject who had been clinically diagnosed with any eye diseases which may impact upon the treatment, or the subject's ability to be assessed after treatment
3. Subjects with intraocular lens (IOL) implant in either eye
4. Planned replacement of crystalline lens with intraocular lens (IOL) implant within the planned study period
5. Subject with shallow anterior chamber
6. Subject who have had a fluorescence angiogram or any use of fluorescein within the last 3 days
7. Subject presenting eye infection or eye damage in either eye
8. Any condition which could interfere with the subject's ability to comply with the study including participation in all study assessments and visits.
9. Subject who had undergone a treatment using photodynamic drugs within the last 30 days. (Including but not limited to methylene blue, toluidine blue, Visudyne®, Foscan, Photofrin or 5-aminolevulinic acid/ALA)
10. Subject diagnosed with any other health condition which, in the opinion of the Investigator, would pose a safety risk to the subject by participating in the study, or may interfere with or jeopardise the study evaluation, procedures or completion
11. Subject currently receiving treatment in another investigational study or has completed another investigational study within the last 30 days
12. Subject participated in the previous study with the LEDINBIO CE Device (EB-14-LAT)
13. Females who are pregnant or lactating
14. Females who are of childbearing potential (menses within the last 12 months) and not taking adequate contraceptive precautions are excluded from the trial. Females of childbearing potential taking acceptable contraceptive precautions may be included.

Primary outcomes:
measure: Change in Visual Acuity
timeFrame: 4 weeks
Secondary outcomes:
measure: Change in Cataract Severity
timeFrame: 4 weeks
measure: Subjective satisfaction using Visual Function Index
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Liepaja
country: Latvia
facility: Lens-L Ltd
city: Riga
country: Latvia
facility: Dr.Solomatina Acu Centrs
city: Ventspils
country: Latvia
facility: Zielmelkurzeme Regional Hospital
city: Kaunas
country: Lithuania
facility: The Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos, Department of Ophthalmology
city: Vilnius
country: Lithuania
facility: Vilnius University Hospital Santaros Klinikos, Center of Eye Diseases
city: Bucharest
country: Romania
facility: Spitalul Clinic de Urgențe Oftalmologice, Depatement of Ophthamology
city: Cluj-Napoca
country: Romania
facility: Vedis Ophthalmology Clinic | Ophthalmological Center Dr. Samoila
city: Timisoara
country: Romania
facility: CF Timisoara Clinical Hospital
city: Timişoara
country: Romania
facility: Opticlass Ophthalmology Clinic
city: Timişoara
country: Romania
facility: Clinica de Oftalmologie Dr. Berghian
city: Timişoara
country: Romania
facility: Clinica Vista, Ophtalmology Department
Study officials:
affiliation: Edinburgh Biosciences Ltd
name: Trevor Shields
role: STUDY_DIRECTOR
References: